Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OGX-011 and Docetaxel in Advanced Breast Cancer
NCT00258375Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2005
- Primary completion
- Feb 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of custirsen in breast cancer, sponsored by Canadian Cancer Trials Group. Started Oct 2005; status: completed.
02
Drugs
custirsen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00258375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258375.